Company Filing History:
1 out of 1 
1 out of 19 Years Active: 2019
Title: Ye-song Gu: Innovator in Cancer Risk Assessment
Introduction
Ye-song Gu is a notable inventor based in Taichung, Taiwan. He has made significant contributions to the field of cancer research, particularly in the assessment of oral cancer risk. His innovative work focuses on the development of biomarkers that can aid in early detection and prevention strategies.
Latest Patents
Ye-song Gu holds a patent for a peptide, specifically a THLW peptide, which is represented by the amino acid sequence SEQ ID No. 1. This peptide serves as a biomarker for diseases such as oral cancer and cervical cancer, which are associated with human papilloma virus (HPV) infections. The patent outlines a method for assessing the risk of developing cancer by utilizing this peptide, making it a valuable tool for healthcare providers.
Career Highlights
Throughout his career, Ye-song Gu has worked with esteemed institutions, including Tunghai University and Taichung Veterans General Hospital. His research has focused on the intersection of molecular biology and oncology, contributing to advancements in cancer diagnostics.
Collaborations
Ye-song Gu has collaborated with notable colleagues, including Feng-Di Lung and Bor-rung Ou. These partnerships have enhanced his research efforts and expanded the impact of his work in the scientific community.
Conclusion
Ye-song Gu's innovative contributions to cancer risk assessment through his patented peptide highlight the importance of early detection in improving patient outcomes. His work continues to inspire advancements in cancer research and diagnostics.